Schering on possible TRA partners
Talks with pharmaceutical companies about a potential collaboration on its Phase III thrombin receptor antagonist for atherothrombosis have reached a stumbling block because potential partners have no comparably valuable asset to offer in return, CEO Fred Hassan said during the Morgan Stanley CEOs Unplugged conference Jan. 3. The firm is apparently looking for a quid pro quo relationship: "We are asking them to show us a quid that has the same kind of value so that we can diversify on both sides, and unfortunately for the larger companies they have nothing to show us. That is the biggest challenge," he said. Schering has "talked to practically all the big companies" and remains open to further discussions, he added. Schering announced its interest in partnering on TRA several months ago 1("The Pink Sheet" Oct. 29, 2007, p. 5)...
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.